XML 93 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
Liability Related to Sale of Future Revenues - Additional Information (Detail) - USD ($)
 12 Months Ended
Nov. 17, 2022
Nov. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Transaction costs related to sale of future revenues     $ 0 $ 1,453,000 $ 0
Total revenue     147,752,000 140,734,000 235,309,000
Drug Product Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     $ 18,753,000 $ 11,086,000 962,000
NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Transaction costs related to sale of future revenues   $ 1,700,000      
Effective annual interest rate related to sale of future revenues     16.03% 19.67%  
NovaQuest Capital Management [Member] | Payment Cap Date on or before December 31, 2028 [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Maximum payment cap amount   100,000,000      
NovaQuest Capital Management [Member] | Payment Cap Date on or after January 1, 2029 [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Maximum payment cap amount   112,500,000      
NovaQuest Capital Management [Member] | Payment Cap Date after January 1, 2030 [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Maximum payment cap amount   125,000,000      
Minimum [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Prepayment amount of 2024 to 2030   80,000,000      
Minimum [Member] | NovaQuest Capital Management [Member] | Payment Period One [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue interest payment   62,500,000      
Minimum [Member] | NovaQuest Capital Management [Member] | Payment Period Two [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue interest payment   125,000,000      
Maximum [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Prepayment amount of 2024 to 2030   125,000,000      
Product [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     $ 100,949,000 $ 82,869,000 47,638,000
Product [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue interest payment   10,000,000      
License [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     9,649,000 22,590,000 116,434,000
Other Revenue - Contract Manufacturing [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     18,401,000 24,189,000 $ 70,275,000
Astellas Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future revenue granted   $ 50,000,000      
Percentage of revenue interest on global net sales   100.00%      
Received from sale of revenue $ 49,800,000        
Gross proceeds received from sale of revenue $ 50,000,000        
Astellas Agreement [Member] | Regulatory Milestone [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue       25,000,000  
Astellas Agreement [Member] | Drug Product Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     18,800,000 11,100,000  
Non-cash interest expense related to drug product revenue     $ 7,700,000 1,000,000  
Astellas Agreement [Member] | Development Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue       2,400,000  
Astellas Agreement [Member] | Maximum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue payment cap amount       125,000,000  
Astellas Agreement [Member] | Product [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of revenue sold   22.50%      
Astellas Agreement [Member] | Milestone payments [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of revenue sold   10.00%      
Astellas Agreement [Member] | Milestone payments [Member] | Payment Period One [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of revenue sold   20.00%      
Astellas Agreement [Member] | License [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue       $ 22,600,000